Recombinant fragment (around aa1-200) of human IGHG4 protein (exact sequence is proprietary)
Alternative Names:
Ig gamma 4 chain C region, IGHG4, Immunoglobulin heavy constant gamma 4 (G4m marker)
IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by an elevated serum IgG4 level, sclerosing fibrosis, and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. Clinical manifestations are apparent in the pancreas, bile duct, gall bladder, lacrimal gland, salivary gland, retroperitoneum, kidney, lung, breast, thyroid, and prostate. Immunohistochemical analyses in the case of IgG4-related sclerosing disease not only exhibit significantly more than normal IgG4-positive plasma cells in affected tissues but also significantly higher IgG4/IgG ratios (typically > 30%). IgG4 antibodies will dominate the IgG response in schistosomiasis, lymphatic filariasis, and in patients after allergen immunotherapy. Unlike the other IgG subclasses, IgG4 does not activate complement. A combined IgA-IgG4 deficiency has been associated with recurrent pyogenic infections.
200ug/ml of Ab produced in CHO cell mammalian-based expression system. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
Formalin-fixed, paraffin-embedded human tonsil stained with IgG4 (Fc) Recombinant Rabbit Monoclonal Antibody (IGHG4/13367R). Inset: PBS instead of primary antibody, secondary only negative control.
* VAT and and shipping costs not included. Errors and price changes excepted
